Aims & Scope
Journal of Alzheimer's Disease Reports is an open access international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, hypotheses, and case reports. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer's disease.
George Perry, PhD
College of Sciences, University of Texas at San Antonio,
One UTSA Circle
San Antonio, Texas 78249
Tel.: +1 210 458 4450
Fax: +1 210 458 4445
Department of Pathology, Case Western Reserve University
2103 Cornell Road, Cleveland, Ohio 44106
Tel.: +1 216 502 2019
J. Wesson Ashford, MD, PhD
Stanford School of Medicine; Palo Alto VA Health Care System, Palo Alto, CA
Craig S. Atwood, PhD
University of Wisconsin-Madison, Madison
Jesús Ávila, MD
Universidad Autónoma de Madrid, Madrid
Rudy J. Castellani, MD
Western Michigan University, Kalamazoo, MI
Sergio T. Ferreira, PhD
Federal University of Rio de Janeiro, Rio de Janeiro
Robert Friedland, MD
University of Louisville, Louisville, KY
Daniela Galimberti, PhD
University of Milan, Milan
Alan Lerner, MD
Case Western Reserve University, Cleveland, OH
Ricardo Maccioni, PhD
International Center for Biomedicine, Santiago
Patrizia Mecocci, MD, PhD
University of Perugia, Perugia
Paula Moreira, PhD
University of Coimbra, Coimbra
Akihiko Nunomura, MD, PhD
University of Yamanashi, Yamanashi
Giulio Maria Pasinetti, MD, PhD
Mount Sinai School of Medicine, New York, NY
Marwan N. Sabbagh, MD
Barrow Neurological Institute, Phoenix, AZ
Thomas B. Shea, PhD
UMass Lowell, Lowell, MA
Massimo Tabaton, MD
University of Genova, Genova
Xiongwei Zhu, PhD
Case Western Reserve University, Cleveland, OH
SUBMISSION OF MANUSCRIPT
PLEASE SUBMIT YOUR MANUSCRIPT HERE
Note that only papers accepted for publication are subject to payment of an article processing charge of US$1450 / EUR1250 to publish under the CC-BY-NC 4.0 license. (There are no article submission charges for this journal.)
Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript.
The article type (Research Report, Review, Short Communication, Hypothesis, etc.) should be clearly mentioned in the cover letter to help the editorial process.
This journal operates with single-blind peer review. If the author prefers double-blind peer review, then please submit your manuscript excluding the author listing and make sure your document is anonymized, and list your authors and affiliations only in the cover letter for the Editor. Each paper is evaluated by at least two peer reviewers and the Editor-in-Chief.
Note that the manuscript should be uploaded as one file with tables and figures included. This file can be a Word document, a PDF, or an embedded compressed file (.zip, .rar) if separate high resolution figures or a supplemental file such as a video are also to be included with the submission (the file size maximum for a video is 25 MB). If the video is too large to submit, please contact email@example.com to arrange a file transfer. For more information about submitting supplementary data see “Supplementary Material.”
Resubmissions should include the manuscript number in the cover letter. The author's replies to the reviewer comments should be included within the revised manuscript itself (at the top). The revised paper should always be a Word document.
ETHICS POLICIES AND PATIENT PERMISSIONS
Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. The author must state compliance in the cover letter and in the Methods section of the article.
Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals. The author must state compliance in the cover letter and in the Methods section of the article.
Preferably patients in figures should be unrecognizable. Authors are responsible for obtaining patient permission for use of the material from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, or hospital numbers anywhere in the manuscript (including figures).
PEER REVIEW POLICY
Journal of Alzheimer’s Disease Reports adheres to the Committee on Publication Ethics (COPE) code of conduct for editors and reviewers [https://publicationethics.org/resources/guidelines-new/cope-ethical-guidelines-peer-reviewers]. Our guidelines should be read in conjunction with this broader guidance. All studies must be conducted to a high ethical standard and must adhere to local regulations and standards for gaining scrutiny and approval.
Journal of Alzheimer’s Disease Reports operates a rigorous, timely, single-blinded peer review process (double-blind on request). After automatic plagiarism screening through iThenticate, manuscripts submitted to the Journal of Alzheimer’s Disease Reports will be assessed for suitability for publication in the journal by the Editor-in-Chief or an assigned Associate Editor. Manuscripts that are deemed unsuitable may be rejected without peer review. Manuscripts that are deemed suitable for peer review are sent to appropriate anonymous referees (a minimum of two) for confidential review. Referee reports are then assessed by the handling Editor, who will send a decision letter to the author along with the anonymized referee reports. All decision letters are approved by the Editor-in-Chief.
The initial decision will be one of the following: rejection, acceptance without revision, or potentially acceptable after minor or major revisions. Revised manuscripts will then be appraised by the Editor-in-Chief or handling Editor, who may seek the opinion of referees (prior or new) before making a final decision. Once approved this decision is then conveyed to the author along with the referee reports. Once accepted manuscripts are published online in the current Volume's run-on content.
The Editor-in-Chief has ultimate responsibility for what is published in the journal. Authors may appeal decisions by contacting the Editor-in-Chief (at firstname.lastname@example.org). Authors will be informed in writing of the result of their appeal.
PREPARATION OF MANUSCRIPTS
Organization and style of presentation
- Manuscripts must be written in English. Authors whose native language is not English are recommended to seek the advice of a native English speaker, if possible, before submitting their manuscripts. Peerwith offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.
- Nomenclature for amyloids should follow the 2018 guidelines of the International Society of Amyloidosis (ISA) nomenclature committee (Amyloid 25, 215-219, 2018), e.g., amyloid-β (Aβ) and amyloid-β protein precursor (AβPP). Also preferred is Aβ42and sAβPPα.
- Manuscripts should be double spaced throughout with wide margins (2.5 cm or 1 in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom. Do not number headings or subheadings (use all caps, italics, then underline). Footnotes should be avoided.
- There are no page or word limits for Research Reports but manuscripts over 10,000 words (Introduction through Discussion) should be approved by the Editor-in-Chief before submission.
- Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation.
- Title (should be clear, descriptive and concise)
- Full name(s) of author(s)
- Full affiliation(s). Delineate affiliations with lowercase letters.
- Present address of author(s), if different from affiliation
- Running title (45 characters or less, including spaces)
- Complete correspondence address, including telephone number, fax number and e-mail address
Leave the author information blank if double-blind peer review is wished for and anonymize your document, but do include the information in the cover letter.
If any author is also a member of the Journal of Alzheimer’s Disease Reports Editorial Board, this should be declared in the Conflict of Interest Section (see instructions in the section for Conflict of Interest).
Changes in Authorship
When submitting the manuscript the author listing and order should be final. If any addition, deletion or rearrangement of author names in the authorship list does need to be made after submission, this can be done only before acceptance and with the Editor’s approval. To request such a change, the Editor must receive the following from the corresponding author: (1) the reason for the change in author list and (2) written confirmation from all authors, including the affected author, that they agree with the addition, removal or rearrangement.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an issue, any requests approved by the Editor will result in an Erratum.
Abstract and Keywords
-The abstract for research papers should follow the "structured abstract" format:
The abstract should try to be no longer than 250 words.
- For other papers such as Reviews, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words.
- Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.
- Note that ALL articles must include an abstract.
Materials and Methods
If applicable to the study, Ethics statements and/or patient permissions must be included in the Materials and Methods section (see top of this page “ETHICS POLICIES AND PATIENT PERMISSIONS”
If there are no acknowledgments, then do still include this section and insert: “The authors have no acknowledgments to report.”
If there is no funding involved, then do still include this section and insert: “The authors have no funding to report.”
Conflict of Interest
If there is no conflict of interest to declare, do still include this section and insert "The authors have no conflict of interest to report". If an author is also on the Editorial Board of this journal, the following statement should be included in this section: “<AUTHOR> is an Editorial Board member of this journal, but was not involved in the peer-review process nor had access to any information regarding its peer review.’’
(Download the EndNote style (the same as for Journal of Alzheimer’s Disease) from EndNote (https://endnote.com/style_download/journal-of-alzheimers-disease/). A .csl file is available here.
- Place citations as numbers in square brackets in the text in order of appearance (inside/before punctuation). Each citation should be to one manuscript only. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (Author(s), unpublished data).
- All authors should be listed in the reference list.
- Please include DOI numbers for "in press" articles if available.
- Carefully check for and remove any duplicates (especially when using reference software).
- References should be listed in the order of appearance in the following style:
 Alzheimer Research Forum, Drugs in Clinical Trials: AAB-001, http://www.alzforum.org/drg/drc/detail.asp?id=101, Last updated May 29, 2007, Accessed on January 29, 2008.
 Smith MA (2006) Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss! In Alzheimer's Disease: A Century of Scientific and Clinical Research, Perry G, Avila J, Kinoshita J, Smith MA, eds. IOS Press, Amsterdam, pp. 305-308.
 Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, Takahashi K, Weiner HL, Tabira T (2004) Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 6, 483-488.
 Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney.
 Zhu X, Perry G, Smith MA (2004) Two hits and you're out? A novel mechanistic hypothesis of Alzheimer disease, Alzheimer Research Forum, http://www.alzforum.org/res/adh/cur/zhu/default.asp, Posted 23 October 2004, Accessed 29 January 2008.
If you are using EndNote and the journal names are not properly abbreviating, please try updating your Journals Term List (https://community.endnote.com/t5/EndNote-How-To/Problems-with-Journal-name-abbreviations/td-p/3003).
Datasets and Data Articles
All datasets and data articles referenced in your manuscript should be cited in the main reference list of your article (not in a separate box or in the article text).
- Number according to their sequence in the text. The text should include references to all tables.
- Provide each table on a separate page of the manuscript after the references.
- Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.
- Citations in the tables should be numbered and included in the Reference list.
The author is required to have obtained patient permission from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, or hospital numbers in the legend, figure, or anywhere in the manuscript.
- Number the figures according to their sequence in the text. The text should include references to all figures.
- Figures should preferably be formatted in TIF or EPS format. JPG is also acceptable.
- Figures should be designed with the format of JMP in mind and preferable sized as they will appear in the pdf. A single column of the journal is 77mm and two columns are 165mm.
- Figures should be at 300 dpi or higher and be cropped to include the figure only (no blank space). CMYK is preferred for color figures.
- On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.
- Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.
- Color figures are free in the electronic version of the journal (this journal is not printed).
Supplementary material is peer-reviewed material directly relevant to the conclusion of a paper that cannot be included in the PDF for reasons of space or medium (for example, large excel tables, movie clips or sound files). The supplement will be available for download from the publisher's content library site at the time of publication and will be made available in the format in which it was provided.
Supplementary material should be included at the end of the main manuscript at the time of submission. In the case of sound/movie files, these can be submitted separately to the Managing Editor (email@example.com) at the time of submission. Supplementary tables and figures must have a separate numbering system from that used for tables and figures that appear in the print version of the paper (the first figure displayed should be labeled "Supplementary Figure 1", the first table "Supplementary Table 1", and so on). References should also be cited in supplements started with  and listed separately.
Supplementary files are limited to 10 MB, except videos which can be up to 25 MB.
Supplementary material for Short Communications is limited to 500 words and 1 table or figure.
Review Articles should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Review Articles should be prepared as detailed above for a Research Report, omitting Introduction through Discussion, and include a conclusion. An abstract must also be included. The length of the Review Article is at the discretion of the author but should be within reasonable limits. The Editor-in-Chief can be consulted regarding reviews of unusual length (>10,000 words).
Systematic reviews or meta-analyses that include a methods section are typically considered as a Research report and should be formatted as such.
A short communication is an article of original scholarship of unusual interest of less than 2000 words (Introduction through Discussion). An abstract of 100 words or less should be included with no subdivison of text into sections. References should be formatted as above. A total of three tables and/or figures are allowed.
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.
Commentaries can be around 1000 words with an abstract and no other subdivisions.
REMEMBER TO INCLUDE
In cover letter:
- Name, postal address, phone number, fax number and e-mail address of the corresponding author.
- Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- A list of at least 4-6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.
- Statement that procedures involving experiments on human subjects are done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975.
- Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.
- Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
- Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the the acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.
Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included at the top of the manuscript. Please submit a tracked version of the paper so editors and reviewers can easily find the changes, or otherwise highlight the edited sections by color or by another detectable way.
All affiliations with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or in financial competition with the subject matter or materials discussed in the manuscript are completely disclosed in the letter of submission.
All financial and material support for this research and work are clearly identified in the manuscript including listing of support specified in the letter of submission that might constitute or give the appearance of influencing the findings, based on the judgment of the Editor-in-Chief in consultation with the Associate Editor handling the review of the manuscript.
PRE-PRESS AND PROOFS
Accepted articles will be placed online as "pre-press" articles shortly after acceptance. This process will occur before the author receives proofs. The pre-press file will remain as the uncorrected proof version until the article is published in an issue and the final published version replaces the pre-press file.
The corresponding author will receive a pdf proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.
The Journal of Alzheimer’s Disease Reports is a fully open access journal. More information about open access publishing in IOS Press journals can be found here: IOS Press Open Library.
Policy regarding the NIH Public Access Policy mandate (PubMed Central)
All articles published in Journal of Alzheimer’s Disease Reports are automatically transferred to Pubmed Central by the publisher within 1 month from the final publication date.
Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.
Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.
COMPLIMENTARY COPY AND PURCHASE
The corresponding author of a contribution to this journal will receive a PDF copy of their published article on release.
An author is entitled to 25% discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.
HOW TO PROMOTE YOUR WORK
Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.
Web of Science: Emerging Sources Citation Index
Sign Up for Mailings – The open access Journal of Alzheimer's Disease Reports (JADR) publishes one volume per year. We issue quarterly mailings and you can sign up for them here. To view the JADR Volume 5 mailing featuring content published during Q2 2021, click here.